Quick Read – JNJ just raised its quarterly dividend 3.1% to $1.34, marking 64 consecutive years of growth backed by nearly 2x cash flow coverage. – Despite STELARA sales crashing 60%, JNJ’s remaining Innovative Medicine portfolio grew 17%, driving overall revenue up 10% in Q1…
26. – At a forward P/E of 20 and beta of 0.26, JNJ still delivered 58% returns over the past year without carrying a growth-stock valuation. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today
I keep hitting the buy button on Johnson & Johnson (NYSE:JNJ) because I have stopped trying to find a more reliable income engine for the back half of my life. Every time I look at the rest of my portfolio and feel the urge to do something clever, I add more JNJ instead. It is the position I never have to babysit.
The thesis is simple. I want a check that shows up, grows a little every year, and is backed by a business diversified enough that no single product failure can break the payout. JNJ has been doing exactly that for longer than I have been alive.